



Fig 3. (A) Kaplan-Meier curves of progression-free survival (PFS) in the intent-to-treat population. Crosses indicate censored patients. (B) Subanalysis of PFS in key clinical subgroups. FISH, fluorescence in situ hybridization; HR, hazard ratio; IHC, immunohistochemistry.